<DOC>
	<DOC>NCT00286013</DOC>
	<brief_summary>The aim of the study is to evaluate the feasibility defined as overall tolerance and toxicity as well as relative dose-intensity and cumulative dose delivered, of an association ofgemcitabine, oxaliplatin and radiotherapy in patients with locally advanced and unresectable, but non-metastatic pancreatic adenocarcinoma or cholangiocarcinoma</brief_summary>
	<brief_title>Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proven and unresectable adenocarcinoma of the pancreas or cholangiocarcinoma with no evidence of metastatic disease WHO performance status of 0 or 1 Complete recovrey from surgery in case an enteric and/or biliary tract bypass operation has been performed Maximum delay after surgery: 8 weeks No previous or coexistent malignant disease except non melanoma skin cancers and adequately treated cervic carcinoma in situ Adequate bon marrow reserve No previous chemotherapy or radiotherapy Expected survival &gt; 6 months Active infection Metastatic disease Inadequate liver function after derivative surgery Inadequate renal function Pregnancy, breast feeding Use of any other investigational agent in the month before enrollment Patients with grade 2 or more neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>